Kornimate/medical-research-clean huggingface dataset:
microwave ablation versus liver resection for intrahepatic cholangiocarcinoma

Conditions: Overall Survival; Disease-free Survival

Summary: thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (hcc), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (icca) is lacking. the goal of this observational study is to study the efficacy of ablation in treating icca by comparing its prognosis with surgery. the main questions it aims to answer are: * whether microwave ablation could achieve similar efficacy with liver resection in treating icca * what is the risk factor for ablation or surgery in treating icca * what kind of icca patients could receive ablation as their first-line treatment in this real-world multicenter cohort study, we will collect data of icca patients from hospitals who underwent microwave ablation (mwa) or liver resection (lr) for tumors within milan criteria. survival will be compared between patients treated by mwa or lr.


Eligibility criteria:
inclusion criteria: 1. pathologically diagnosed icca based on the who classifications; 2. curative-intent liver resection or microwave ablation; 3. tumor within milan criteria, namely single tumor ≤5cm in maximum diameter; multiple tumors ≤3 in number and each ≤3cm; no evidence of major vascular/hilar invasion, extrahepatic/lymphatic metastasis or other malignancies; 4. age ≥18 years. exclusion criteria: patients not meeting any one of the inclusion criteria were excluded.
a study of diflucan in children with ringworm of the scalp

Conditions: Tinea Capitis

Summary: the purpose of this study is to evaluate the safety and efficacy of fluconazole for the treatment of tinea capitis in pediatric patients aged 3 to 12 years.


Eligibility criteria:
inclusion criteria: * pediatric patients (aged 3-12 years) * clinical diagnosis of tinea capitis * direct microscopy (koh) positive for fungal elements within or outside hair shaft exclusion criteria: * negative baseline koh * liver disease
tissue-resident memory t cells expression in melasma

Conditions: Melasma

Summary: the treatment of melasma and the maintenance of depigmentation represent a challenge due to its frequent recurrences. pathophysiological mechanisms and factors have been linked to melasma such as inflammation, sun exposure, increased cd4+ t lymphocytic infiltrate and il-17 in damaged skin. tissue-resident memory t cells (trm), derived from naïve t lymphocytes, are associated with the recurrence of lesions at the same sites but they have not been described in melasma. this a cross-sectional, prospective analytical study. 20 female patients, 18 to 55 years of age, with diagnosis of melasma and mmasi score of at least 7, at least 1-year duration, lesional and perilesional skin biopsies were taken for pcr and dif. the objective is to determine the transcription factors of trm cells in malar melasma.

melasma is a common, acquired pigmentary disorder characterized by chronic and relapsing hypermelanosis on sun-exposed areas that causes significant emotional and psychosocial impact in patients mainly in women with fitzpatrick iii-v phototypes. the treatment of melasma and the maintenance of depigmentation represents a challenge due to its frequent recurrences. different pathophysiological mechanisms and factors have been linked to melasma such as inflammation, sun exposure, increased cd4+ t lymphocytic infiltrate and il-17 in damaged skin. in pathologies such as vitiligo and psoriasis, tissue-resident memory t cells (trm), derived from naïve t lymphocytes, are associated with the recurrence of lesions at the same sites. these cells have a specific profile of transcription factors (runx3+, notch+, blimp1+) and cd69 + cd103 + markers. these cells have not been described in melasma. objective: to determine the transcription factors of trm cells in malar melasma. this is a cross-sectional, prospective analytical study. 20 female patients, 18 to 55 years of age, with diagnosis of melasma and mmasi score of at least 7, at least1 year duration, and no treatment in the last 4 weeks, were included. lesional and perilesional skin biopsies were taken for pcr and dif. the presence of trm cells has not been described or studied in melasma where there is recurrence of the dermatosis in the same site, it is essential to understand its pathogenesis in order to address directed future therapies targeting these cells that may related to the disease.

Eligibility criteria:
inclusion criteria: female patients with malar melasma, healthy volunteers 18 years of age and older, without previous treatment or photoprotection measures within the previous 4 weeks, who had at least 7 modified melasma activity and severity index (mmasi) score exclusion criteria: * exclusion criteria were pregnancy or nursing, menopause, coexistence of other pigmentation conditions, heat exposure, regular exer- cise, diet restriction, consumption of food supplements or any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months, and women who had given birth within 1 year

Keywords: blimp-1 runx-3 transcription factors tissue-resident memory t cells
an follow-up study of liver cirrhosis

Conditions: Decompensated Liver Cirrhosis

Summary: this is a follow-up study to assess safety and preliminary clinical activity of adr-001 in patients with liver cirrhosis (child-pugh score; grade b) caused by hepatitis c or nonalcoholic steatohepatitis. patients who have already participated in the adr-001-01 study and completed the last evaluation after 24 weeks of administration will be eligible to this study. patients registered will continue follow-up observation and evaluate long-term safety and exploratory efficacy.


Eligibility criteria:
inclusion criteria: * liver cirrhosis patients enrolled in adr-001-01 study and completed the last observation of the study * voluntary signed informed consent exclusion criteria: * patients evaluated by investigators as inappropriate
nicotinamide riboside supplementation and exercise training to promote healthy longevity

Conditions: Healthy Aging; Lifestyle-related Condition; Metabolic Diseases

Summary: the prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. these age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. nicotinamide adenosine dinucleotide (nad) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. importantly, it has been shown that high cellular nad+ levels as well as a high nad+/nadh ratio promote metabolic and mitochondrial health. in contrast, nad+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. these findings fuel the notion of boosting the nad+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. supplementation with nicotinamide riboside (nr), a naturally occurring form of vitamin b3, boosts cellular nad+ levels. however, in contrast to animal studies, nr supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. interestingly, recently, it has been suggested that metabolic conditions where nad+ levels become limited, is needed for nr supplementation to exert beneficial health effects. this metabolic condition could be achieved by exercise. however, studies combining nr and exercise are lacking, and that is why we will perform the present study.


Eligibility criteria:
inclusion criteria: * participants are able to provide signed and dated written informed consent prior to any study specific procedures * aged ≥ 60 and ≤ 80 years * body mass index (bmi) 25 - 35 kg/m2 * stable dietary habits (no weight loss or gain \> 5 kg in the past 3 months) * no signs of active cardiovascular disease, liver or kidney malfunction exclusion criteria: * patients with congestive heart failure and and/or severe renal and or liver insufficiency * uncontrolled hypertension * any contra-indication for mri scanning * alcohol consumption of \> 3 servings per day for man and \>2 servings per day for woman * smoking * unstable body weight (weight gain or loss \> 5kg in the last 3 months) * engagement in structured exercise activities \> 2 hours a week * previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the investigator which would possibly hamper our study results * use of food supplements containing nr or resveratrol (similar working mechanisms)
studding the implementation of eras protocols in pediatric surgery

Conditions: ERAS; Pediatric Disorder; Appendicitis; Hydrocele

Summary: this is a retrospective cohort, descriptive study, investigating the role of eras protocols, in pediatric surgery and evaluate the feasibility and effectiveness of implementing these protocols


Eligibility criteria:
inclusion criteria: * all patients aged 6months -18 years, who underwent pediatric surgeries at a single tertiary institution exclusion criteria: * patients who had co-morbidities that might affect the outcome of the enhanced recovery and those who were younger than 6 months.

Keywords: enhanced recovery after surgery (eras) enhanced recovery protocol fast-track surgery pediatric surgery
feasibility of an online exercise community among individuals with type 2 diabetes

Conditions: Type 2 Diabetes; Type2diabetes; Diabetes Mellitus, Type 2; Type2 Diabetes Mellitus

Summary: the aim of this study is to evaluate the feasibility, fidelity and acceptability of an 8-week high intensity online physical exercise combined with online group meetings and supported with an activity tracker in individuals with type 2 diabetes. the design of the intervention will be developed using a co-creation approach. the intervention consist of eight weeks of 30 minutes online physical exercise followed by 30 minutes of online group meeting in microsoft teams once a week. outcomes includes pre-defined research progression criteria and secondary outcomes of physical and mental health and participant feedback.

the study is designed as a one-armed feasibility for the reason that the progression criteria are linked to the intervention. no blinding will be applied in the study. the study will be carried on the centre for physical activity research, rigshospitalet, denmark. reporting of the study will be following the consort extension to a randomized pilot and feasibility trials. participants will be recruited from the capital region of denmark and region zealand using different recruitment strategies followed by a telephone screening with the project coordinator.

Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes * access to a device such as a computer, tablet, or a smart phone exclusion criteria: * contraindications to exercise, for example heart conditions, complications/injuries in the locomotive apparatus * advised to not exercise by medical doctor * current participation in other intervention trials

Keywords: obesity feasibility physical activity type 2 diabetes
emotional brain networks & cognitive functioning in depression and anxiety

Conditions: Major Depressive Disorder; General Anxiety Disorder

Summary: this study aims to 1) examine common and specific emotional and cognitive dysfunctions between major depression and generalized anxiety disorder; 2) examine emotional and cognitive dysfunctions between the two disorders and healthy controls; 3) examine the biomarkers predicting successful therapy or not.


Eligibility criteria:
inclusion criteria: * gad: 1. diagnosis of generalized anxiety disorder (gad) according to dsm v criteria in a structured clinical interview for dsm-v axis i disorders (scid i; apa, 2014) and a confirmatory clinical interview 2. duration of the current episode \> 3 weeks * mdd: 1. diagnosis of current major depressive disorder in a structured clinical interview for dsm-v axis i disorders (scid i; apa, 2014) and a confirmatory clinical interview 2. duration of the current episode \> 4 weeks exclusion criteria: * gad: diagnosis of any other psychiatric axis i disorder (except gad) as a principal diagnosis within the past six months * mdd: diagnosis of any other psychiatric axis i disorder (except mdd) as a principal diagnosis within the past six months

Keywords: emotional impairments cognitive impairments
probiotics and endotoxemia

Conditions: Metabolic Endotoxemia; Metabolic Syndrome

Summary: the purpose of this study is to determine whether probiotic treatment of overweight volunteers consuming high fat diet is able to reduce plasma lipopolysaccharide concentration.


Eligibility criteria:
inclusion criteria: * body mass index ≥ 27 kg/m2; above 18 years of age * used to eat high fat diet (more than 40% of total energy intake) exclusion criteria: * treated cardiovascular risk factors, treated hypertension, treated dyslipidemia, treated diabetes; known diabetes, hypertension, dyslipidemia * severe illnesses * artificial heart valve * immunosuppression * regular consumption of probiotics * history of bariatric surgery * consumption or wish to consume orlistat * participation in other research * pregnancy or wishing/trying to get pregnant * inability to follow protocol.
efficacy and safety study of low dose oral contraceptive pill to treat dysmenorrhea

Conditions: Dysmenorrhea

Summary: the purpose of this study is to determine whether combination oral contraceptive pill of norethindrone \& ethinyl estradiol is effective in the treatment of dysmenorrhea associated with endometriosis.


Eligibility criteria:
inclusion criteria: * dysmenorrhea associated with endometriosis exclusion criteria: * severe hepatopathy * pregnant woman
the importance of the number of incisions in the effectiveness of dry needling

Conditions: Neck Pain

Summary: the dry needling technique is a procedure increasingly used by health professionals. dry needling consists of the use of a filiform needle to treat musculoskeletal pain. currently, the mechanisms by which it is an effective technique are not well understood. one of the aspects not yet evaluated is the best dose in terms of the number of times it is necessary to insert the needle into the patient to achieve the best result. this research work aims to assess which treatment obtains the best results in the management of patients with chronic neck pain.

with the objective of demonstrating how the dose used during the application of the dry needling technique is related to the effectiveness of the treatment, we have designed a study where three different doses of the dry needling technique for the treatment of myofascial trigger points will be compared in the upper trapezius muscle in participants with neck pain. randomly, the participants will be distributed to each of the treatment groups and we will measure how the effectiveness of each of the applied doses determines the result of the application of the dry needling technique in the treatment of neck pain.

Eligibility criteria:
inclusion criteria: * nonspecific mechanical neck pain for more than 3 months. * neck pain of at least vas 5/10. * reproduction of pain and symptoms subjects on palpation. * pain on passive stretching of the muscle. exclusion criteria: * subjects with previous surgical intervention. * subjects undergoing other intervention (rehabilitation/medication). * positive findings that raise suspicion of cervical radiculopathy: * subjects diagnosed: degenerative arthropathies, inflammatory, systemic conditions (fibromyalgia). * cardiovascular diseases. * whiplash or whiplash. * belenophobia. * dizziness and vertigo. * pregnant. * thyroid disorders.

Keywords: dry needling myofascial trigger point
the effect of ultrasound-guided erector spinae plane block on postoperative analgesia in radiofrequency ablation therapy

Conditions: Hepatocellular Carcinoma

Summary: this is a double blind, randomized controlled trial to evaluate the efficacy of espb(erector spinae plane block) on postoperative analgesia in rfa( radiofrequency ablation therapy). we will include 80 patients, and randomly assign to espb(chirocaine) group and control group(normal saline).we deduce erector spinae plane block can be use as a postoperative analgesic way for patients who receive radiofrequency ablation of hepatocellular carcinoma.

computed tomography guided radiofrequency ablation of hepatocellular carcinoma(hcc) has became a popular way to treat hcc. although the wound is small and the patients can discharge on the next day, they have to suffer from moderate to severe pain. nowadays erector spinae plane block has been applied to many surgery as a postoperative analgesic strategy. we deduce erector spinae plane block can be use as a postoperative analgesic way for patients who receive radiofrequency ablation of hepatocellular carcinoma. besides, we will add contrast medium to evaluate the spread area of local anesthetics.

Eligibility criteria:
patients undergoing computed tomography guided radiofrequency ablation of hepatic tumor under scheduled general anesthesia, and fulfilled one of following inclusion criteria: 1. diameter of hepatic tumor is larger than 2 cm 2. distance of tumor site is near the hepatic surface \< 2cm exclusion criteria: 1. a history of allergic reaction to local anesthetics or iohexol 2. renal insufficiency, creatinine clearance \< 30ml/min 3. coagulopathy or other bleeding disorder that cannot perform nerve block 4. under pregnancy or lactation 5. opioid tolerant patient

Keywords: hepatocellular carcinoma radiofrequency ablation erector spinae plane block
comparison of 24-hour holter monitoring versus 14-day continuous ecg patch monitoring ezypro

Conditions: Atrial Fibrillation; Arrhythmias, Cardiac

Summary: this is an open-label study to investigate the functional features of prolonged monitoring by 14-day ezypro® to improve the medical care and/or diagnosis for the patient with arrhythmia. patients will be enrolled by outpatient basis from two clinical study sites. enrolled patients will wear a traditional 24-hour holter monitor and an 14-day ezypro® which can provide monitoring data for up to 14 days. this study will allow a direct comparison between two devices.


Eligibility criteria:
inclusion criteria: * provision of signed written informed consent before enrollment into the study * are able to communicate with the investigators * with suspected arrhythmia related signs and symptoms, judged by the investigators * patients intend to wear ecg moniotrs * males and females, 20 years of age or older exclusion criteria: * patients with skin allergies or injury, judged by investigators * patients with specific arrhythmia or specific treatments, interfere with study evaluations, judged by investigators * pregnant women * currently participating in another trial or who participated in a previous clinical trial

Keywords: atrial fibrillation arrhythmias, cardiac ezypro ecg recorder ecg monitor long term ecg monitor 14-day ecg monitor
bilateral ultrasound guided quadratus lumborum versus lumbar epidural block on postoperative analgesia, and inflammatory response in abdominal surgery

Conditions: Postoperative Pain; Inflammatory Response

Summary: this study aims at comparing the effects of bilateral ultrasound-guided quadratus lumborum block versus lumbar epidural block on postoperative analgesia and inflammatory response following major lower abdominal cancer surgery.


Eligibility criteria:
inclusion criteria: * asa ii, iii * weight 50 - 85 kg. * scheduled for major lower abdominal cancer surgery (radical cystectomy, total abdominal hysterectomy). exclusion criteria: * patients with a history of relevant drug allergy. * coagulation disorders. * opioid dependence. * sepsis. * local infection at the vicinity of the block site. * patients with psychiatric illnesses that would interfere with perception and assessment of pain
autophagy induction after bortezomib for myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to better understand the effects of the chemotherapy medication bortezomib on cancer cells. the investigators are therefore taking blood and bone marrow samples from patients with myeloma who are receiving bortezomib to see if the investigators can detect autophagy in the myeloma cells from the bone marrow and in immune cells in the blood. subjects are eligible if their doctor is planning to treat them with bortezomib for the first time for their myeloma.

primary objective: the primary objective of this study is to determine whether administration of bortezomib leads to an increase in cellular autophagy, as determined by electron micrographs of peripheral blood lymphocytes and primary myeloma cells in patients receiving single-agent bortezomib. secondary objectives 1. to determine the optimal timing of autophagy assessments for patients receiving bortezomib. 2. to explore whether high levels of autophagy are associated with resistance to bortezomib therapy. 3. to validate our primary assay by confirming baseline stability of the number of autophagic vesicles per cell 4. to compare results of autophagy measurements in peripheral blood mononuclear cells and bone marrow plasma cells

Eligibility criteria:
inclusion criteria: * histologically confirmed multiple myeloma (both newly diagnosed and relapsed patients are permitted) * no more than one line of prior therapy containing bortezomib. no prior therapy with any other proteasome inhibitor. * for subjects who received previous bortezomib, at least a partial response while on the bortezomib-containing therapy, without progression while on bortezomib-containing therapy or within 90 days of stopping bortezomib. * planned therapy, as determined by the patient's treating physician, with a bortezomib-containing regimen * medically suitable to undergo study procedures, including a one-week washout of prior therapy, one week of observation, and one week of single-agent bortezomib * provision of written informed consent exclusion criteria * age \<18 years (though the demographics of myeloma make it highly unlikely that any children will meet inclusion criteria) * treatment with other anti-myeloma agents, including corticosteroids, thalidomide, or lenalidomide, within the 7 days prior to the study baseline bone marrow biopsy. * inability to understand the informed consent document or unwillingness to consent. * written informed consent must be obtained from all patients before study entry.

Keywords: multiple myeloma bortezomib proteasome inhibitor